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 CURRENTOPINION Precision medicine and skin cancer therapy:
dealing with a moving target
Reinhard Dummer
After years of standstill, there are today new
avenues to treat cutaneous malignancies. Intense
basic research applying the most advanced techno-
logy has resulted in a deep understanding of
the molecular biology and the genetic background
of basal cell carcinoma (BCC), melanoma and other
malignancies.
BCC today is considered as a malignancy that is
highly dependent on an activated sonic hedgehog
pathway.Most BCCs present inactivatingmutations
of patch that acts as a tumor suppressor in BCC or
activating mutations in smoothened that can be
considered as an oncogenic driver in the disease.
Mutations in these key players of the hedgehog
signaling pathway are involved in more than 90%
of all BCCs. Consequently, there was an urgent
need for the development of small molecules that
interfere with the function of smoothened such
as vismodegib or sonidegib and others [1]. As an
activated hedgehog pathway appears to be a con-
dition sine qua non in BCC, most tumors have
responded with tumor shrinkage during systemic
therapy with these inhibitors. However, there are
still many open questions about the detailed mech-
anism of action, the impact of immune responses
and the optimal scheduling of these inhibitors. The
toxicity profile of these drugs nicely illustrates
where hedgehog signaling is still needed in the adult
human being. The maintenance and metabolism of
muscle cells, the biochemical processes of tasting
and the initiation of the hair follicle cycle depend on
hedgehog signaling, and consequently are affected
during systemic therapy with smoothened inhibi-
tors. The principal open question in this context is:
can a systemic therapy with smoothened inhibitors
cure advanced or metastatic BCC? This might be
possible only in the minority of patients; however,
the addition of further treatment modalities
and molecules, such as EGF-R-inhibitors, MEK-
inhibitors or other treatment modalities including
immunotherapy might contribute to increase the
cure rate.
In contrast to BCC, which is characterized by
an activated hedgehog signaling pathway in most,
if not all, cases, melanoma appears to be a very
heterogeneous disease. Actually, we shall talk
today about themelanomas.We have to distinguish
melanomas derived from melanocytes associated
with the epidermis from other sites such as ocular
origin or dermal origin in the context of congenital
nevi [2] or naevus blue. Even in the group ofmucosal
melanoma there appears to be a difference between
mucosal melanoma derived from sinonasal mucosa
versus mucosal melanomas derived from genital
mucosa. These differences are clinically relevant as
the frequency of a c-Kit mutation is much higher
in vulvovaginal melanomas in comparison with
sinonasal melanoma [3]. Still there is clear evidence
that the activation of the MAP-kinase pathway is
a key driver in the majority of the melanomas.
Activating mutations for BRAF and NRAS are well
known genetic causes. Intelligent pharmacology has
provided us with a number of specific and potent
inhibitors of the kinases BRAF and MEK [4] that
play a crucial role in this pathway and additional
inhibitors that interfere with ERK or RAS are in
preclinical or early clinical development.
The second promising avenue in the develop-
ment of new therapeutic strategies is immuno-
therapy. There is a modest activity of interferon
alpha in early stages of metastatic melanoma, there
are impressive data on the impact of adoptive cell
transfer in a selected patient population with meta-
staticmelanoma and now there is the promise of the
use of immune check point blocking agents such
as ipilimumab, nivolumab and lambrolizumab.
Modern vaccines are additional attractive tools in
this repertoire [5].
For the first time in dermato-oncology, we have
today promising predictivemarkers for the outcome
of a therapy, such as the BRAFmutation for targeted
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therapy using vemurafenib and other BRAF
inhibitors and the expression of PD1L for the use
of anti-PD1 antibodies in advanced cancers, such as
melanoma renal cell cancer and lung cancer. How-
ever, very recently we had to experience that
these predictive markers are not stable during the
course of a malignant disease. The expression of
PD1L is affected by interferon gamma secreted by
infiltrating CD8þ lymphocytes [6]. In addition,
recent investigations also suggest that the percent-
age of BRAF mutated cells within one melanoma
lesion can be reduced during therapy with respect-
ive inhibitor and additional tumor clones with other
driver mutations can evolve [7].
We must conclude that (skin) cancers are
adaptive and moving targets tremendously impact-
ing on the long-term benefit of the new treatment
approaches.
We will need to gather all the knowledge from
basic research and clinical skills to deal with these
challenging circumstances.
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